Nautilus Biotechnology Files Q1 2025 10-Q

Ticker: NAUT · Form: 10-Q · Filed: Apr 29, 2025 · CIK: 1808805

Nautilus Biotechnology, INC. 10-Q Filing Summary
FieldDetail
CompanyNautilus Biotechnology, INC. (NAUT)
Form Type10-Q
Filed DateApr 29, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, biotechnology, reporting

Related Tickers: ARIA

TL;DR

Nautilus Bio (NAUT) filed its Q1 2025 10-Q, showing financial updates. No major surprises yet.

AI Summary

Nautilus Biotechnology, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as ARYA Sciences Acquisition Corp III, is focused on laboratory analytical instruments. The filing details financial data for the first quarter of 2025, including changes in common stock and additional paid-in capital.

Why It Matters

This filing provides investors with an update on Nautilus Biotechnology's financial position and operational activities for the first quarter of 2025, crucial for assessing the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a biotechnology company, Nautilus faces inherent risks related to research and development, regulatory approvals, and market adoption of its technologies.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Nautilus Biotechnology, Inc.?

Nautilus Biotechnology, Inc. is primarily involved in the business of laboratory analytical instruments, as indicated by its SIC code 3826.

What was the previous name of Nautilus Biotechnology, Inc.?

Nautilus Biotechnology, Inc. was formerly known as ARYA Sciences Acquisition Corp III, with a date of name change on April 8, 2020.

For what period is this 10-Q report filed?

This 10-Q report is filed for the period ended March 31, 2025.

When was this 10-Q report filed with the SEC?

This 10-Q report was filed on April 29, 2025.

What are the key financial statement components mentioned for the period?

The filing mentions components such as Common Stock, Additional Paid-In Capital, Accumulated Other Comprehensive Income, and Retained Earnings for the periods ending March 31, 2025, and December 31, 2024.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on April 29, 2025 regarding Nautilus Biotechnology, Inc. (NAUT).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing